Other Information.
−Removed: None of our directors or officers adopted or terminated a Rule 10b5 - 1 trading arrangement or a non-Rule 10b5 - 1 trading arrangement (as defined in Item 408 (c) of Regulation S-K) during the third quarter of 2024.
+Added: None of our directors or officers adopted or terminated a Rule 10b5 - 1 trading arrangement or a non-Rule 10b5 - 1 trading arrangement (as defined in Item 408 (c) of Regulation S-K) during the first quarter of 2025.
See the Exhibit Index to this Quarterly Report immediately below and before the signature page hereto, which Exhibit Index is incorporated by reference as if fully set forth herein.
28 unchanged sentences
September 10, 2024
−Removed: Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Redeemable Preferred Stock
−Removed: August 21, 2024
−Removed: Form of Securities Purchase Agreement between the Company and the investors thereto, dated August 19, 2024
−Removed: August 21, 2024
−Removed: Form of Registration Rights Agreement by and among the Company and the investors named therein, dated August 19, 2024
−Removed: August 21, 2024
−Removed: Sixth Amendment to Exclusive License Agreement
−Removed: August 21, 2024
−Removed: Second Amendment to At-The-Market Issuance Sales Agreement, dated September 9, 2024
−Removed: September 13, 2024
−Removed: Employment Agreement, dated as of September 12, 2024, by and between Allarity Therapeutics, Inc., and Alexander Epshinsky
−Removed: September 13, 2024
−Removed: Employment Agreement, dated as of September 30, 2024, by and between Allarity Therapeutics, Inc., and Jeremy R.
−Removed: October 4, 2024
Certifications of the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act
7 unchanged sentences
Inline XBRL Taxonomy Extension Presentation Linkbase Document
−Removed: The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, formatted in Inline XBRL (included in Exhibit 101)
−Removed: Schedules (or similar attachments) to this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K.
−Removed: The Company agrees to furnish supplementally a copy of all omitted schedules (or similar attachments) to the Securities and Exchange Commission on a confidential basis upon request.
−Removed: Certain information was redacted from this exhibit pursuant to Item 601(a)(6) of Regulation S-K.
−Removed: Management contracts or compensatory plans or arrangements.
+Added: The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, formatted in Inline XBRL (included in Exhibit 101)
Furnished herewith.
1 unchanged sentence
ALLARITY THERAPEUTICS, INC.,
−Removed: November 14, 2024
/s/ Thomas H.
1 unchanged sentence
(Principal Executive Officer)
−Removed: November 14, 2024
/s/ Alexander Epshinsky
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.